Close Menu

immunocompromised

The Stanford spinout has launched an infectious disease test that sequences cell-free pathogen DNA to diagnose sepsis in immunocompromised patients.

At the recent IDWeek conference, company collaborators presented early validation data on a blood-based assay for cell-free microbial DNA.

Researchers used exome sequencing to pinpoint DOCK2 mutations as causative of early childhood immune deficiency that leads to severe infections. 

BD Diagnostics and Italian biotech firm Biodiversity said today that they will collaborate to develop a comprehensive molecular diagnostic menu for testing immunocompromised patients on the BD Max system, adding to the pipeline of assay content for the recently launched platform.

In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.